Relistor

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification[1] issued on	Commission Decision Issued[2] / amended on	Product Information affected[3]	Summary
IB/0065/G	This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes	11/12/2024		SmPC, Labelling and PL	

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	B.IV.1.z - Change of a measuring or administration device - Other variation				
IAIN/0066	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	06/09/2024	n/a		
IAIN/0064	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	17/06/2024	n/a		
IAIN/0063	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	22/02/2024	n/a		
IAIN/0062/G	This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	04/12/2023		Annex II and PL	
IAIN/0061/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging	21/12/2022	n/a		

	site A.7 - Administrative change - Deletion of manufacturing sites				
IB/0060/G	This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.i - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Where there is no monograph in the European/National Ph. for the AS, a change in specification from in-house to a non-official/third country Ph. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.z - Quality change - Active substance - Other variation B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or	19/12/2022	n/a		

	manufacturer of a novel excipient				
IB/0059/G	This was an application for a group of variations. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.c.1.z - Change in immediate packaging of the AS - Other variation B.I.z - Quality change - Active substance - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder	08/12/2022	n/a		

	or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient				
PSUSA/2023/ 202203	Periodic Safety Update EU Single assessment - methylnaltrexone bromide	01/12/2022	n/a		PRAC Recommendation - maintenance
IAIN/0058	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	28/10/2022	04/10/2023	Annex II and PL	
IA/0056	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	07/07/2021	n/a		
IB/0054	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	19/01/2021	n/a		
IAIN/0055	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	11/12/2020	09/12/2021	Annex II and PL	
T/0053	Transfer of Marketing Authorisation	15/11/2019	16/12/2019	SmPC, Labelling and PL	
PSUSA/2023/	Periodic Safety Update EU Single assessment -	31/10/2019	n/a		PRAC Recommendation - maintenance

201903	methylnaltrexone bromide				
IAIN/0051	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	29/04/2019	n/a		
IB/0050	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	30/01/2019	n/a		
N/0048	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	19/12/2018	16/12/2019	Labelling and PL	
IB/0047/G	This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits	21/03/2018	n/a		

	B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits				
IA/0046/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	06/02/2018	n/a		
IB/0045	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	18/09/2017	n/a		
PSUSA/2023/201603	Periodic Safety Update EU Single assessment - methylnaltrexone bromide	10/11/2016	09/01/2017	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2023/201603.
IAIN/0044/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites	13/07/2016	09/01/2017	Annex II and PL	

	A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release				

	arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing				
N/0042	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	30/05/2016	09/01/2017	PL	
T/0041	Transfer of Marketing Authorisation from TMC Pharma Services Ltd. to PharmaSwiss Ceska Republika s.r.o Transfer of Marketing Authorisation	21/12/2015	28/01/2016	SmPC, Labelling and PL	Transfer of Marketing Authorisation from TMC Pharma Services Ltd. to PharmaSwiss Ceska Republika s.r.o
II/0039	B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF	26/11/2015	n/a		
PSUSA/2023/201503	Periodic Safety Update EU Single assessment - methylnaltrexone bromide	08/10/2015	n/a		PRAC Recommendation - maintenance
IB/0040/G	This was an application for a group of variations. B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products	21/09/2015	n/a		

	B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products				
IA/0037/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	08/06/2015	n/a		
II/0030	Extension of Indication to include the treatment of opioid-induced constipation in non-cancer adult patients when response to laxative therapy has not been sufficient; as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. C.I.6.a - Change(s) to therapeutic indication(s) -	23/04/2015	27/05/2015	SmPC and PL	Please refer to the scientific discussion Relistor EMEA/H/C/000870/II/30 for further information.

	Addition of a new therapeutic indication or modification of an approved one				
PSUV/0032	Periodic Safety Update	09/10/2014	n/a		PRAC Recommendation - maintenance
IB/0035	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	22/08/2014	11/09/2014	SmPC	
IAIN/0034	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	25/07/2014	n/a		
IA/0033	B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information	10/07/2014	n/a		
IAIN/0031/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release	23/06/2014	11/09/2014	Annex II and PL	

	arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing				
II/0029	The MAH submitted for assessment the CSR of a randomised controlled trial after preliminary closure and as requested by PRAC during the assessment of PSUR 8. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	20/03/2014	n/a		The purpose of the study was to assess the safety and efficacy of methylnaltrexone in the Asian patient population and to evaluate the pharmacokinetics profile in Asian subjects. The study was closed due to the infeasibility to recruit a sufficient number of patients. There were no safety concerns leading to termination. Overall, efficacy and safety results revealed nothing substantially new. No change to the Product Information was considered necessary based on these results.
II/0028	Update of section 4.8 of the SmPC in order to add vomiting as an undesirable effect. The Package Leaflet is updated accordingly. Furthermore, the PI is being brought in line with the latest QRD template version 9. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data	19/09/2013	11/09/2014	SmPC, Annex II and PL	
IAIN/0027	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	15/07/2013	n/a		

IB/0026	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	26/06/2013	n/a		
R/0022	Renewal of the marketing authorisation.	21/03/2013	27/05/2013	SmPC, Annex II, Labelling and PL	Based on the CHMP review of the available information and on the basis of a re-evaluation of the benefit risk balance, the CHMP is of the opinion that the quality, safety and efficacy of Relistor continues to be adequately and sufficiently demonstrated and therefore considered that the benefit risk profile of Relistor continues to be favourable in the Treatment of opioid-induced constipation in advance illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient.
N/0024	To include an additional warning on the tray label of the vial presentation to state that the syringe needle retracts after use. The MAH also took the opportunity to add the contact email address for TMC Pharma Services Ltd. in the package leaflet for Estonia, Finland, France, Malta and Slovakia in order to make consistent with the annexes for the rest of the Member States. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	21/01/2013	27/05/2013	Labelling	
IAIN/0023	A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release	14/12/2012	27/05/2013	Annex II and PL	

IA/0021	A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)	31/08/2012	n/a		
II/0018	Update of section 5.3 of the SmPC to reflect the results of carcinogenicity studies RPT-74168 in mice and RPT-74169 in rats. Furthermore the MAH took the opportunity to adapt the PI to the current QRD template, and to delete the DDPS version number from Annex II. B. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data	23/06/2011	27/07/2011	SmPC, Annex II and PL	Two 104-week oral gavage carcinogenicity studies in cesarean-derived (CD)-1® mice and Sprague-Dawley (S-D) rats were performed. In these studies, male and female rats were administered oral doses up to 300 mg/kg/day (approximately 4 times the exposures (AUC) in humans at the subcutaneous dose of 0.15 mg/kg) and mice were administered oral dosages up to 200 mg/kg/day for males or 400 mg/kg/day for females (approximately 13 times and 21 times, respectively, the exposure (AUC) in humans at the subcutaneous dose of 0.15 mg/kg). Both studies did not show carcinogenic potential for methylnaltrexone.
T/0019	Transfer of Marketing Authorisation	14/06/2011	05/07/2011	SmPC, Labelling and PL	
WS/0117	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.8.b - Introduction of a new Pharmacovigilance system - which has been assessed by the relevant NCA/EMA for another product of the same MAH	14/04/2011	17/06/2011	Annex II	
IA/0017	A.7 - Administrative change - Deletion of manufacturing sites	04/11/2010	n/a		

X/0006	Annex I_2.(d) Change or addition of a new pharmaceutical form	24/06/2010	06/09/2010	SmPC, Labelling and PL	Based on the CHMP review of data on quality, safety and efficacy, the CHMP considered by consensus that the risk-benefit balance of Relistor pre-filled syringes 8 mg/ 0.4 ml and 20 mg/ 0.6 ml in the treatment of opioid induced constipation in advanced illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient was favourable and therefore recommended the granting of the marketing authorisation.
II/0016	Update of section 4.4 and 4.8 of the SmPC to add information relating to intestinal perforation following a cumulative review of medically confirmed cases of gastrointertinal perforation. The Package leaflet is updated accordingly. The MAH also took the opportunity to a correct section 4.8 to reorder the listed 'Very Common' adverse reactions under Gastrointestinal Disorders in order of importance. This variation application is submitted further to the request of the CHMP following assessment of PSUR Nr. 3, covering the period 28.03.09 - 27.09.09. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data	22/07/2010	01/09/2010	SmPC and PL	A review of spontaneous postmarketing reporting until 31 March 2010 identified 10 cases of gastrointestinal perforation medically confirmed. Although patients who experienced gastrointestinal perforation had conditions that may be associated with localized or diffuse reduction of structural integrity in the wall of the gastrointestinal tract such as cancer, peptic ulcer or pseudo-obstruction, Relistor may have contributed to these events. Therefore in order to increase awareness of prescribers and patients and in order to facilitate early diagnosis and treatment of such event a warning is added in the product information. Healthcare professional are recommended to use methylnaltrexone bromide with caution in patients with known or suspected lesions of the gastrointestinal tract. It is also advised to patients to promptly report severe, persistent, and/or worsening of gastrointestinal symptoms. The event gastrointestinal perforation is also added to section 4.8 of the SmPC as new undesirable effect observed in postmarketing setting.
II/0008	Update of section 5.3 of the SmPC as a result of the completion of non-clinical tolerability and toxicity studies in juvenile rats and dogs. In addition the MAH took the opportunity to make some language	20/05/2010	05/07/2010	SmPC and PL	Studies have been conducted in juvenile rats and dogs. Following intravenous injection of methylnaltrexone bromide, juvenile rats were found to be more sensitive than adult rats to methylnaltrexone-related toxicity. In

	corrections to the German and Slovakian versions of the SmPC. The full list of local representatives is also updated in the Package Leaflet. Paediatrics to validate Update of Summary of Product Characteristics and Package Leaflet				juvenile rats administered intravenous methylnaltrexone bromide for 13 weeks, adverse clinical signs (incidences of convulsions and laboured breathing) occurred at dosages (? 3 mg/kg/day) and exposures (5.4 times the exposure [AUC] in adult humans at a subcutaneous dose of 0.15 mg/kg) that were lower than those that caused similar toxicity in adult rats (20 mg/kg/day). No adverse effects occurred in juvenile rats at 1 mg/kg/day or in adult rats at 5 mg/kg/day (1.6 times and 7.8 times, respectively, the exposure [AUC] in adult humans at a subcutaneous dose of 0.15 mg/kg). Following intravenous injection of methylnaltrexone bromide for 13 weeks, similar methylnaltrexone related toxicity was observed in both juvenile and adult dogs. In adult and juvenile dogs given methylnaltrexone bromide at 20 mg/kg/day, clinical signs indicative of CNS toxicity and prolongation of QTc interval were observed. No adverse effects occurred in either juvenile or adult dogs at a dose of 5 mg/kg/day (44 times the exposure {AUC} in adult humans at a subcutaneous dose of 0.15 mg/kg).
IB/0015	B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product	05/05/2010	n/a	SmPC, Labelling and PL	
IB/0014	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	05/05/2010	n/a	SmPC	
IA/0013	C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of	22/04/2010	n/a	Annex II	

	the pharmacovigilance system				
IA/0012	C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities	22/04/2010	n/a	Annex II	
IA/0011	C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD	22/04/2010	n/a	Annex II	
IA/0010	C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV	22/04/2010	n/a	Annex II	
IA/0009	C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV	22/04/2010	n/a	Annex II	
II/0007	Update of section 4.8 "Undesirable effects" of the Summary of Product Characteristics to add "hyperhidrosis" based on results of study 3200K1-3356-WW. The PL was amended accordingly. The MAH took the opportunity to update the Package Leaflet with the text from the Patient Instructions and Patient Checklist Card as agreed by the CHMP in Follow-up measure RM2 026.1 on 29 May 2009. The MAH also amended the contact details of the local representative in Austria, Germany, Greece, Malta Portugal and Spain. Typographical errors were also	19/11/2009	21/12/2009	SmPC, Labelling and PL	Results from study 3200K1-3356-WW showed that the event "hyperhidrosis" was reported with a higher rate among the subjects receiving methylnaltrexone bromide than among subjects receiving placebo. Based on the incidence reported in the trial (6.0% to 6.1%) the event is reported in the SmPC with a frequency category of common under the Skin and Subcutaneous tissue disorders system organ class. The PL has been updated accordingly. The Patient Instructions have been updated and a Patient Checklist added in line with the CHMP conclusion on RM2

	corrected throughout the SmPC. Update of Summary of Product Characteristics, Labelling and Package Leaflet				026.1.
II/0003	Update of the DDPS (Module 1.8.1) to reflect a change in the Qualified Person in the EEA for Pharmacovigilance (QPPV). Other administrative and editorial changed are incorporated in this revised DDPS (version 2.1). Annex II of the Product Information has been updated using standard text including the new version number for the DDPS (version 2.1). Changes to QPPV Update of DDPS (Pharmacovigilance)	29/05/2009	03/07/2009	SmPC, Annex II and PL	Update of the DDPS (Module 1.8.1) to reflect a change in the Qualified Person in the EEA for Pharmacovigilance (QPPV). Other administrative and editorial changed are incorporated in this revised DDPS (version 2.1). Annex II of the Product Information has been updated using standard text including the new version number for the DDPS (version 3.0).
IA/0005	IA_05_Change in the name and/or address of a manufacturer of the finished product	19/05/2009	n/a	Annex II and PL	
II/0002	The Marketing Authorisation Holder proposes a limit of not more than 125 ppm for the sum of two degradants. Quality changes	23/04/2009	07/05/2009		
IB/0004	IB_33_Minor change in the manufacture of the finished product	07/05/2009	n/a		
N/0001	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	05/02/2009	n/a	PL	